Abib Agbetoba, MD
Otolaryngology · Bellaire, TXNPI 1164656633
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Intersect ENT, Inc. at 48.8% of the total. Reporting peaked in 2021 at $13,396 and has fallen 89.2% since, to $1,442 in 2025. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $202.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$14K
- Optinose US, Inc.$4K
- Aerin Medical Inc.$3K
- Stryker$2K
- Sanofi$1K
- Medtronic$1K
- plus $3K from 13 others
What the payments were for
- Consulting fees$11,07139%
- Speaking & faculty fees$5,46319%
- Travel & lodging$2,73610%
- Food & beverage$8,87932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 22 | $13,742 |
| Optinose US, Inc. | 15 | $4,157 |
| Aerin Medical Inc. | 13 | $3,258 |
| Stryker | 21 | $1,786 |
| Sanofi | 6 | $1,305 |
| Medtronic(2 entities) | 15 | $1,170 |
| Neurent Medical Limited | 17 | $941 |
| Acclarent, Inc | 8 | $516 |
| Inspire Medical Systems, Inc. | 5 | $326 |
| 3-d Matrix, Inc. | 1 | $183 |
| Hologic Sales And Service, LLC | 1 | $148 |
| Olympus America Inc. | 3 | $147 |
| Integra Lifesciences Corporation | 1 | $137 |
| GSK | 4 | $97 |
| Pacira Pharmaceuticals Incorporated | 1 | $84 |
| Regeneron Healthcare Solutions, Inc. | 2 | $66 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $36 |
| Boston Scientific | 1 | $29 |
| Hikma Pharmaceuticals USA | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$7,585
- Xhance$3,794
- VivAer$1,644
- RhinAer$1,644
- VIVAER STYLUS$907
- RHINAER STYLUS$907
- NEUROMARK Radiofrequency Console$678
- SINUVA$524
- Vivaer RF Stylus$509
- NUVENT$419
- ENTELLUS - XPRESS ENT DILATION SYSTEM$404
- NEUROMARK Device$387
- FIAGON NAVIGATION UNIT$376
- XPRESS ENT DILATION SYSTEM$299
- NEUROMARK System$291
- TruDi Nav Cable$245
- STEALTHSTATION S8 PLATFORM$163
- AUDION ET DILATION SYSTEM$149
- CoolSeal Generator$148
- Inspire$141
How this compares
$28,148 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $44,380 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 26 | $3,427 |
| Epinephrine | 16 | $3,355 |
| Ipratropium Bromide | 52 | $1,952 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 11 | $1,401 |
| Omeprazole | 63 | $528 |
| Fluticasone Propionate | 33 | $496 |
| Azelastine Hcl | 24 | $457 |
| Methylprednisolone | 58 | $377 |
| Cefadroxil | 24 | $208 |
| Mupirocin | 22 | $163 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $153 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $151 |
| Montelukast Sodium | 12 | $117 |
| Gabapentin | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $21 | $3,35516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Bellaire
- Robert PalmerBellaire$53K
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.